Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Wave Life Sciences, Inc.WVE · Entity 4976 | See Remarks | December 07, 2016 | December 09, 2016 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Wave Life Sciences, Inc.
Report date December 07, 2016 · Filed December 09, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 20,000 |
Reported balance
After 2016-12-07 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2016-12-07 · Exercise / conversion · Acquired 20,000 · Balance 20,000 |
| Ordinary SharesSEC Table I · non-derivative | Direct | 4,000 |
Reported balance
After 2016-12-07 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2016-12-07 · Exercise / conversion · Acquired 4,000 · Balance 4,000 |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.47 · Expires 2025-03-22 | Direct | 78,617 |
Reported balance
After 2016-12-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-12-07 · Exercise / conversion · Disposed 20,000 · Balance 78,617 F1: The incentive share option represented a right to purchase a total of 108,617 ordinary shares, 25% of which became exercisable on March 10, 2016, which was the first anniversary on which the option was granted, and the remaining shares vest in 36 equal monthly installments thereafter. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.47 · Expires 2025-03-22 | Direct | 8,629 |
Reported balance
After 2016-12-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2016-12-07 · Exercise / conversion · Disposed 4,000 · Balance 8,629 F2: The non-qualified option represented a right to purchase a total of 12,629 ordinary shares, 25% of which became exercisable on March 10, 2016, which was the first anniversary on which the option was granted, and the remaining shares vest in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The incentive share option represented a right to purchase a total of 108,617 ordinary shares, 25% of which became exercisable on March 10, 2016, which was the first anniversary on which the option was granted, and the remaining shares vest in 36 equal monthly installments thereafter.
F2: The non-qualified option represented a right to purchase a total of 12,629 ordinary shares, 25% of which became exercisable on March 10, 2016, which was the first anniversary on which the option was granted, and the remaining shares vest in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 07, 2016 Filed Dec 9, 2016 18:36 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $2.47 | $0.00 |
DisclosureSEC source: 0000899243-16-035267 · doc4.xml · derivative · entry 4 GUERCIOLINI ROBERTO · CIK 0001286837 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,629 Underlying: Ordinary Shares · 4,000 shares Expires 2025-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The non-qualified option represented a right to purchase a total of 12,629 ordinary shares, 25% of which became exercisable on March 10, 2016, which was the first anniversary on which the option was granted, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| December 07, 2016 Filed Dec 9, 2016 18:36 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.47 | $0.00 |
DisclosureSEC source: 0000899243-16-035267 · doc4.xml · derivative · entry 3 GUERCIOLINI ROBERTO · CIK 0001286837 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,617 Underlying: Ordinary Shares · 20,000 shares Expires 2025-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The incentive share option represented a right to purchase a total of 108,617 ordinary shares, 25% of which became exercisable on March 10, 2016, which was the first anniversary on which the option was granted, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| December 07, 2016 Filed Dec 9, 2016 18:36 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 4,000 | $2.47 | $9,880.00 |
DisclosureSEC source: 0000899243-16-035267 · doc4.xml · nonDerivative · entry 2 GUERCIOLINI ROBERTO · CIK 0001286837 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 07, 2016 Filed Dec 9, 2016 18:36 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 20,000 | $2.47 | $49,400.00 |
DisclosureSEC source: 0000899243-16-035267 · doc4.xml · nonDerivative · entry 1 GUERCIOLINI ROBERTO · CIK 0001286837 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.